{"success":true,"data":{"pressRelease":{"id":"168451","rtpr_id":"nWkr8MsSF-20261014","ticker":"SCIB","exchange":"Nasdaq Stockholm","all_tickers":["SCIB"],"title":"SciBase secures first payer coverage with Highmark, marking a major commercial inflection point","author":"Cision","published_at":"2026-10-14T07:00:14.666Z","article_body":"SciBase\nSWEDEN - October 14, 2026 - SciBase Holding AB (\"SciBase\") [STO: SCIB], a\nleader in advanced technology for the detection and prevention of skin\ndisease, announced today that Nevisense has received its first positive\nmedical policy from Highmark Blue Cross Blue Shield, one of the largest Blue\nCross Blue Shield organizations in the United States.\n\nThe decision marks a major milestone in SciBase's U.S. commercialization\nstrategy and changes the reimbursement landscape for Nevisense. For the first\ntime, eligible use of the technology can move from a predominantly cash-pay\nmodel into covered care through a major U.S. private insurer, reducing one of\nthe most significant barriers to broader clinical adoption.\n\nSciBase has already established strong commercial momentum in the United\nStates without broad private payer reimbursement. The addition of coverage\nintroduces a new growth driver to an existing business, expanding the number\nof dermatology practices and patients that can access Nevisense within a\nreimbursed model.\n\n\"This is a defining milestone for SciBase and an important step forward in the\ndevelopment of our U.S. business,\" said Pia Renaudin, CEO of SciBase. \"\nHighmark coverage begins to remove one of the most important barriers to scale\nand creates the opportunity to reach a substantially larger portion of the\nU.S. market. Reimbursement now becomes an additional driver of growth in a\nbusiness where demand for our technology has already been established.\"\n\nThe United States is SciBase's largest commercial opportunity. Approximately\n6,500 to 7,000 private dermatology clinics operate in the U.S., with around\n6,000 considered relevant for Nevisense, and an estimated 4 to 4.5 million\nskin biopsies are performed annually.\n\nThe Highmark decision represents more than the addition of a new payer. It\nbegins to address one of the principal constraints on U.S. commercial scale\nand creates a pathway to convert established clinical adoption into broader\nreimbursed utilization.\n\nHighmark, together with its Blue-branded affiliates, is one of the largest\nBlue Cross Blue Shield affiliated organizations in the United States, serving\nover 7 million members across multiple states.\n\nFor dermatologists, reimbursement can reduce the financial barrier to\nincorporating Nevisense into care for eligible patients while expanding\npatient access to objective, non-invasive technology that can support the\nassessment of suspicious skin lesions.\n\nSciBase will continue its engagement across the U.S. payer market while\nexpanding commercial activity in geographies where reimbursement is available.\n\nWhat the policy covers\n\nUnder the policy, Highmark considers EIS medically necessary when a\ndermatologist is evaluating a clinically atypical suspicious pigmented lesion\nand is considering a biopsy.\n\nThe procedure is reported with CPT code 0658Tand the key criteria include:\n* Melanoma is part of the differential diagnosis\n* The lesion is on the trunk or extremities and measures 2 mm to 20 mm\n* The patient is 18 or older\n* The lesion is not on a mucosal surface, palm, sole or nail, and is not\nulcerated, bleeding or recently traumatized\n* The device is FDA-approved and used by a dermatologist trained in clinical\nand dermoscopic evaluation of pigmented lesions\n* The policy applies to all Highmark commercial insured lines of business and\nto self-funded (ASO) employer groups that elect it. In support of its\nposition, Highmark cites the NCCN Clinical Practice Guidelines for Cutaneous\nMelanoma (Version 2.2026), which list EIS among technologies that may aid\ndetection of new primary melanoma, and American Academy of Dermatology\nguidance on emerging noninvasive diagnostics.\nThis information is information that SciBase Holding AB is obliged to make\npublic pursuant to the EU Market Abuse Regulation. The information was\nsubmitted for publication, through the agency of the contact person set out\nbelow, at 09:00 AM CEST on October 14, 2026.\n\nFor additional information, please contact:\n\nPia Renaudin, CEO, tel. +46732069802, e-mail: pia.renaudin@scibase.com\n\nCertified Advisor (CA): DNB Carnegie Investment Bank AB (publ) Phone: +46 8\n588 68 570, E-mail: certifiedadviser@carnegie.se\n\nAbout SciBase  \nSciBase is a global medical technology company, specializing in early\ndetection and prevention in dermatology. SciBase develops, manufactures, and\ncommercializes Nevisense, a unique point-of-care platform that combines AI and\nadvanced EIS technology to elevate diagnostic accuracy, ensuring proactive\nskin health management.\n\nOur commitment is to minimize patient suffering, allowing clinicians to\nimprove and save lives through timely detection and intervention and reduce\nhealthcare costs.\n\nBuilt on more than 20 years of research at Karolinska Institute in Stockholm,\nSweden, SciBase is a leader in dermatological advancements.\n\nThe company has been on the Nasdaq First North Growth Market exchange since\nJune 2, 2015 and the company's Certified Adviser is Carnegie Investment Bank\nAB (publ).  Learn more at www.scibase.com. For press releases and financial\nreports visit: http://investors.scibase.se/en/pressreleases\n\nhttps://news.cision.com/scibase/r/scibase-secures-first-payer-coverage-with-highmark--marking-a-major-commercial-inflection-point%2Cc4408544\n\nPR Highmark - eng (https://mb.cision.com/Main/12371/4408544/4316990.pdf)\n\n\n\n(c) Cision 2026","article_body_html":"","raw_payload":{"data":{"id":"nWkr8MsSF-20261014","title":"SciBase secures first payer coverage with Highmark, marking a major commercial inflection point","author":"Cision","ticker":"SCIB","created":"2026-10-14T07:00:14.666Z","tickers":["SCIB"],"exchange":"Nasdaq Stockholm","article_body":"SciBase\nSWEDEN - October 14, 2026 - SciBase Holding AB (\"SciBase\") [STO: SCIB], a\nleader in advanced technology for the detection and prevention of skin\ndisease, announced today that Nevisense has received its first positive\nmedical policy from Highmark Blue Cross Blue Shield, one of the largest Blue\nCross Blue Shield organizations in the United States.\n\nThe decision marks a major milestone in SciBase's U.S. commercialization\nstrategy and changes the reimbursement landscape for Nevisense. For the first\ntime, eligible use of the technology can move from a predominantly cash-pay\nmodel into covered care through a major U.S. private insurer, reducing one of\nthe most significant barriers to broader clinical adoption.\n\nSciBase has already established strong commercial momentum in the United\nStates without broad private payer reimbursement. The addition of coverage\nintroduces a new growth driver to an existing business, expanding the number\nof dermatology practices and patients that can access Nevisense within a\nreimbursed model.\n\n\"This is a defining milestone for SciBase and an important step forward in the\ndevelopment of our U.S. business,\" said Pia Renaudin, CEO of SciBase. \"\nHighmark coverage begins to remove one of the most important barriers to scale\nand creates the opportunity to reach a substantially larger portion of the\nU.S. market. Reimbursement now becomes an additional driver of growth in a\nbusiness where demand for our technology has already been established.\"\n\nThe United States is SciBase's largest commercial opportunity. Approximately\n6,500 to 7,000 private dermatology clinics operate in the U.S., with around\n6,000 considered relevant for Nevisense, and an estimated 4 to 4.5 million\nskin biopsies are performed annually.\n\nThe Highmark decision represents more than the addition of a new payer. It\nbegins to address one of the principal constraints on U.S. commercial scale\nand creates a pathway to convert established clinical adoption into broader\nreimbursed utilization.\n\nHighmark, together with its Blue-branded affiliates, is one of the largest\nBlue Cross Blue Shield affiliated organizations in the United States, serving\nover 7 million members across multiple states.\n\nFor dermatologists, reimbursement can reduce the financial barrier to\nincorporating Nevisense into care for eligible patients while expanding\npatient access to objective, non-invasive technology that can support the\nassessment of suspicious skin lesions.\n\nSciBase will continue its engagement across the U.S. payer market while\nexpanding commercial activity in geographies where reimbursement is available.\n\nWhat the policy covers\n\nUnder the policy, Highmark considers EIS medically necessary when a\ndermatologist is evaluating a clinically atypical suspicious pigmented lesion\nand is considering a biopsy.\n\nThe procedure is reported with CPT code 0658Tand the key criteria include:\n* Melanoma is part of the differential diagnosis\n* The lesion is on the trunk or extremities and measures 2 mm to 20 mm\n* The patient is 18 or older\n* The lesion is not on a mucosal surface, palm, sole or nail, and is not\nulcerated, bleeding or recently traumatized\n* The device is FDA-approved and used by a dermatologist trained in clinical\nand dermoscopic evaluation of pigmented lesions\n* The policy applies to all Highmark commercial insured lines of business and\nto self-funded (ASO) employer groups that elect it. In support of its\nposition, Highmark cites the NCCN Clinical Practice Guidelines for Cutaneous\nMelanoma (Version 2.2026), which list EIS among technologies that may aid\ndetection of new primary melanoma, and American Academy of Dermatology\nguidance on emerging noninvasive diagnostics.\nThis information is information that SciBase Holding AB is obliged to make\npublic pursuant to the EU Market Abuse Regulation. The information was\nsubmitted for publication, through the agency of the contact person set out\nbelow, at 09:00 AM CEST on October 14, 2026.\n\nFor additional information, please contact:\n\nPia Renaudin, CEO, tel. +46732069802, e-mail: pia.renaudin@scibase.com\n\nCertified Advisor (CA): DNB Carnegie Investment Bank AB (publ) Phone: +46 8\n588 68 570, E-mail: certifiedadviser@carnegie.se\n\nAbout SciBase  \nSciBase is a global medical technology company, specializing in early\ndetection and prevention in dermatology. SciBase develops, manufactures, and\ncommercializes Nevisense, a unique point-of-care platform that combines AI and\nadvanced EIS technology to elevate diagnostic accuracy, ensuring proactive\nskin health management.\n\nOur commitment is to minimize patient suffering, allowing clinicians to\nimprove and save lives through timely detection and intervention and reduce\nhealthcare costs.\n\nBuilt on more than 20 years of research at Karolinska Institute in Stockholm,\nSweden, SciBase is a leader in dermatological advancements.\n\nThe company has been on the Nasdaq First North Growth Market exchange since\nJune 2, 2015 and the company's Certified Adviser is Carnegie Investment Bank\nAB (publ).  Learn more at www.scibase.com. For press releases and financial\nreports visit: http://investors.scibase.se/en/pressreleases\n\nhttps://news.cision.com/scibase/r/scibase-secures-first-payer-coverage-with-highmark--marking-a-major-commercial-inflection-point%2Cc4408544\n\nPR Highmark - eng (https://mb.cision.com/Main/12371/4408544/4316990.pdf)\n\n\n\n(c) Cision 2026"},"type":"article","timestamp":"2026-10-14T07:00:14.766105836Z","server_sent_at_ms":1791961214766},"received_at":"2026-10-14T07:00:14.822Z","source_url":"https://news.cision.com/scibase/r/scibase-secures-first-payer-coverage-with-highmark--marking-a-major-commercial-inflection-point%2Cc4408544"},"analysis":{"id":"156717","press_release_id":"168451","analysis_json":{"industry":{"label":"Health Care Equipment & Supplies","sector":"Health Care"},"redFlags":["No quantified revenue or utilization guidance tied to the new coverage","U.S. listing absent -- trades on Nasdaq First North in Stockholm, limiting U.S. investor access"],"eventType":"regulatory","narrative":"SciBase secured its first positive medical policy from Highmark Blue Cross Blue Shield, making Nevisense eligible for reimbursed use in the U.S. for the first time.\n\nCoverage applies to EIS evaluation of clinically atypical pigmented lesions via CPT code 0658T, across Highmark commercial lines and electing self-funded employer groups serving over 7 million members.\n\nThe shift from cash-pay to covered care removes a key adoption barrier in a market of roughly 6,000 relevant dermatology clinics and 4 to 4.5 million annual skin biopsies, though no revenue impact was quantified.","sentiment":"bullish","agentHooks":{"shouldPost":true,"suggestedAngle":"First U.S. payer coverage for Nevisense converts cash-pay momentum into a reimbursed growth channel -- watch for additional payer wins."},"keyFigures":{"customDimensions":{"cpt_code":"0658T","highmark_members":"over 7 million","annual_us_skin_biopsies":"4 to 4.5 million","us_private_derm_clinics":"6,500 to 7,000","relevant_clinics_for_nevisense":6000}},"quotedText":"Highmark coverage begins to remove one of the most important barriers to scale and creates the opportunity to reach a substantially larger portion of the U.S. market.","namedEntities":{"people":[{"name":"Pia Renaudin","role":"CEO"}],"products":["Nevisense"],"companies":[{"name":"SciBase Holding AB","ticker":"SCIB","relationship":"filer"},{"name":"Highmark Blue Cross Blue Shield","relationship":"payer/insurer"},{"name":"DNB Carnegie Investment Bank AB","relationship":"certified adviser"},{"name":"Karolinska Institute","relationship":"research origin"}],"dollarAmounts":[]},"materialImpact":{"score":3,"reasoning":"First-ever positive medical policy from a major U.S. private insurer (Highmark BCBS) shifts Nevisense from cash-pay to reimbursed care, removing a key adoption barrier. Material commercial catalyst, but no revenue figures or quantified financial impact disclosed."},"tickerRelevance":{"others":[],"primary":"SCIB"},"globalImportance":35,"audienceRelevance":15,"eventTypeSecondary":["operations_update"],"importanceComponents":{"tickerTier":"micro-cap foreign issuer","eventGravity":"first payer coverage milestone","householdBrandBoost":false,"marketCapAdjustment":"material for small company but niche audience"}},"event_type":"regulatory","event_type_secondary":["operations_update"],"sentiment":"bullish","material_impact_score":3,"narrative":"SciBase secured its first positive medical policy from Highmark Blue Cross Blue Shield, making Nevisense eligible for reimbursed use in the U.S. for the first time.\n\nCoverage applies to EIS evaluation of clinically atypical pigmented lesions via CPT code 0658T, across Highmark commercial lines and electing self-funded employer groups serving over 7 million members.\n\nThe shift from cash-pay to covered care removes a key adoption barrier in a market of roughly 6,000 relevant dermatology clinics and 4 to 4.5 million annual skin biopsies, though no revenue impact was quantified.","key_figures":{"customDimensions":{"cpt_code":"0658T","highmark_members":"over 7 million","annual_us_skin_biopsies":"4 to 4.5 million","us_private_derm_clinics":"6,500 to 7,000","relevant_clinics_for_nevisense":6000}},"named_entities":{"people":[{"name":"Pia Renaudin","role":"CEO"}],"products":["Nevisense"],"companies":[{"name":"SciBase Holding AB","ticker":"SCIB","relationship":"filer"},{"name":"Highmark Blue Cross Blue Shield","relationship":"payer/insurer"},{"name":"DNB Carnegie Investment Bank AB","relationship":"certified adviser"},{"name":"Karolinska Institute","relationship":"research origin"}],"dollarAmounts":[]},"model_name":"glm-5.3-flashx","prompt_hash":"sha256:5c812bd9e28b810d","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-10-14T07:00:20.892Z","global_importance":35,"audience_relevance":15,"importance_components":{"tickerTier":"micro-cap foreign issuer","eventGravity":"first payer coverage milestone","householdBrandBoost":false,"marketCapAdjustment":"material for small company but niche audience"}},"durationMs":6057,"modelName":"glm-5.3-flashx"}}